Progenics Pharma (PGNX) Tops Q2 Views; Revs Heavy
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Price: $4.10 --0%
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
VIVE, ENSV, MDLM, More
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
VIVE, ENSV, MDLM, More
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q2 EPS of $1.64, versus the analyst estimate of ($0.25). Revenue for the quarter came in at $74.41 million versus the consensus estimate of $9.98 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Gap, Inc. (GAP) Tops Q2 EPS by 3c
- Dollar Tree (DLTR) Tops Q2 EPS by $1.59, Beats on Revenue; Offers FY Guidance
- Build-A-Bear Workshop (BBW) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
